03/06/23 4:02 PMNasdaq : NVAX conferenceshigh shortNovavax to Participate in TD Cowen's 43rd Annual Health Care ConferenceNovavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen's 43 rd Annual Health Care Conference. About Novavax Novavax, Inc. promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious...RHEA-AIneutral
03/02/23 5:00 PMNasdaq : NVAX high shortNovavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non-qualified stock option and restricted stock units to Elaine O'Hara, its newly appointed Chief Strategy Officer, as a material inducement for her entry into employment with Novavax, effective as of March 1, 2023.RHEA-AIvery positive
02/28/23 4:02 PMNasdaq : NVAX earningshigh shortNovavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsNovavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2022. "I am excited to be joining Novavax at this important time in the company's history," said John C. Jacobs, President and Chief...RHEA-AIneutral
02/21/23 4:02 PMNasdaq : NVAX conferencesearningshigh shortNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023Novavax, Inc., a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets. About Novavax Novavax, Inc. promotes improved health by...RHEA-AIneutral
02/13/23 8:00 AMNasdaq : NVAX partnershipcovid-19high shortU.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 VaccineNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, todayRHEA-AIneutral
01/25/23 5:00 PMNasdaq : NVAX high shortNovavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has granted a non-qualified stock option and restricted stock units to John C. Jacobs, its newly appointed President and Chief Executive Officer, as a material inducement for his entry into...RHEA-AIvery positive
01/18/23 8:00 AMNasdaq : NVAX covid-19high shortNovavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult BoosterNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketingRHEA-AIneutral
01/09/23 9:00 AMNasdaq : NVAX high shortNovavax Names John C. Jacobs as New President & Chief Executive OfficerCurrent President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline developmentRHEA-AIvery positive
12/30/22 8:00 AMNasdaq : NVAX clinical trialcovid-19high shortNovavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine CandidatesNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza CombinationRHEA-AIneutral
12/28/22 5:00 PMNasdaq : NVAX offeringhigh shortNovavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common StockOn December 20, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, completed the closing of its previouslyRHEA-AIneutral